ゲノム編集の決定版ガイド。
★
メニュー
ホーム 学ぶ ニュース
探索する 技術 疾患 治療法 臨床試験 企業 科学者 遺伝子 研究 研究機関
医療を超えて 農業 倫理 投資 世界地図
学ぶ・ツール まずはここから 用語集 A~Z 技術を比較する タイムライン リスト・ランキング AIエージェント ★ 保存済み API
このサイトについて 私たちについて 方法論 データソース 編集方針 お問い合わせ 免責事項

ガイドビュー
遺伝学が初めてですか? 閲覧しながら、すべての用語をわかりやすく説明します。同じページに、サポートが組み込まれています。

専門家の見解
生物学はすでにご存知の方へ。コンテンツだけをすっきりとコンパクトに、余分な説明なしでお届けします。これがデフォルト表示です。

表示言語
ライトモード
Two empty chairs facing each other with a balance scale above

CRISPR Decoded

Ethics

The arguments this technology forces, presented with the strongest case on each side, not a verdict.

8 ethics in CRISPR Decoded. Each topic shows the strongest argument on both sides before you open it. CRISPR Decoded does not take a position.

8 表示中

Germline and heritable genome editing

Editing embryos, eggs or sperm would change every cell of a future person and be passed to their descendants, which is why it is…

Proponents argue

For couples where both partners carry two copies of a recessive disease variant, no embryo can be free of it. Preimplantation selection cannot help, and…

Critics argue

Consent is impossible: the person most affected does not exist yet and their descendants never will be asked.

5 このページで要約されている管轄区域

Enhancement and 'designer babies'

The question of editing for traits rather than disease, where the science is much weaker than the debate assumes.

Proponents argue

Parents already shape children's traits through education, nutrition, medicine and environment; genetic means are not obviously different in kind.

Critics argue

The polygenic reality means promised enhancements are largely unachievable, so the debate risks legitimising claims that cannot be delivered.

Disability, difference and what counts as a disease

Whether some conditions gene editing could eliminate are diseases to be treated or forms of human variation: a question the…

Proponents argue

Many conditions cause severe pain, organ damage and early death; treating them is not a statement about anyone's worth.

Critics argue

Resources directed at eliminating a condition are not directed at accommodating the people who have it.

Access, cost and global equity

A two-million-dollar one-time treatment for a disease concentrated in the world's poorest regions is the field's most concrete…

Proponents argue

High prices fund the development that produced the therapy, and no therapy is worse than an expensive one.

Critics argue

Pricing at what health systems will bear rather than what treatment costs makes universal access structurally impossible.

Gene drives and the environment

Engineered genetic elements designed to spread through a wild population: potentially eliminating malaria, and potentially…

Proponents argue

Malaria kills hundreds of thousands of people a year, most of them children under five; existing tools have plateaued and resistance is rising.

Critics argue

An organism engineered to spread cannot meaningfully be recalled once released.

3 このページで要約されている管轄区域

Biosecurity and dual use

Techniques that make medicine cheaper and faster also make misuse cheaper and faster: the unavoidable dual-use problem.

Proponents argue

Open publication accelerates defensive work on vaccines, diagnostics and therapeutics more than it aids attack.

Critics argue

Some results genuinely lower the barrier to causing harm, and publishing them is a choice.

Consent for permanent change

What informed consent means for a treatment that cannot be stopped, reversed or withdrawn.

Proponents argue

Patients with severe disease are capable of weighing serious risk and are entitled to do so.

Critics argue

'Informed' is hard to achieve when the mechanism is unfamiliar and long-term effects are unknown even to investigators.

Human embryo research

Editing embryos in the laboratory, without transfer to a uterus, is permitted in some countries and prohibited in others, and it…

Proponents argue

It is the only way to understand early human development and why so many pregnancies fail.

Critics argue

Some hold that an embryo has moral status making research use impermissible regardless of benefit.

4 このページで要約されている管轄区域